



# **MediCapital Inc.**

12649 S. Jackson Rd., Edinburg, TX. 78535

## **MEMO**

Date: April 12, 2019  
To: Dr. Brett Millan, CEO, MediCapital, Inc.  
From: Roxanne Arellano, RN Research Manager  
Subject: Investment Research Report

---

MediCapital, Inc. is an accredited nonprofit organization that takes pride and dedication to finding leading companies that are on the cutting edge of medicine and medical breakthroughs. MediCapital, Inc. is looking to invest in these companies to save families by finding the cure for terrible diseases. Current projects consist of finding a cure for cancer by researching companies like Applera Corp-Celera, Onyx Pharmaceuticals, United Therapeutics, Crucell NV, and Mannkind Corporation. The following information was gathered from each company: number of years in business, stock's 52-week high and low, drugs in clinical trials, and partnership details were also researched for investment purposes and ideas.

United Therapeutics and Crucell NV would be great companies to invest in due to their strong and specialized commitment to finding the cure for multiple types of cancer. Both companies have been in business for nineteen plus years which means they are both well-established cancer research companies. Both companies should be highly considered for investment.

Below is a detailed summary for your review of the companies listed above.

### **Applera Corp-Celera**

Applera Corp-Celera has been in business since 1998. In 2008, Applera Corporation announced its separation from Celera and changed its name to Applera Corporation-Applied Biosystems Groups. Applera Corporation specializes and markets instrument-based systems, software, and services, targeting therapeutics for cancer, autoimmune disorders, and inflammatory diseases.

- ◆ *Drugs in Clinical Trials:* N/A
- ◆ *Stock's 52-week high and low:* \$282.98 and \$202.83
- ◆ *Partners:* PE Corporation and MDS SCIEX

### **Onyx Pharmaceuticals**



## **MediCapital Inc.**

12649 S. Jackson Rd., Edinburg, TX. 78535

Onyx Pharmaceuticals has been in business since 1992. Onyx Pharmaceuticals is a biopharmaceutical company that specializes in developing and marketing medication for the treatment of cancer. The company is in collaboration with Bayer HealthCare Pharmaceuticals, Inc., which is currently developing and marketing Nexavar (sorafenib) tablets. These tablets are a small molecule drug that has been approved for the treatment of liver cancer and advanced kidney cancer.

- ♦ ***Drugs in Clinical Trials:***
  - CARB-X - This drug targets drug resistant bacteria highlighted on the CDCs antibiotic resistant threats list. The trial is currently in phase I.
- ♦ ***Stock's 52-week high and low:*** \$210.19 and \$165.22
- ♦ ***Partners:*** Abbot, Accenture, Barney & Barney, LLC., Baxter Healthcare Corporation, Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Novartis, and Pfizer, Inc./Rinat

## **United Therapeutics**

United Therapeutics has been in business since 1996. United Therapeutics is a biotechnological company that is focused on the development of products to help patients with chronic and life-threatening conditions.

- ♦ ***Drugs in Clinical Trials:***
  - Intravenous/Subcutaneous and Oral Treprostinil – This drug would be used to treat pulmonary arterial hypertension. Drug is currently in phase IV.
  - Inhaled Treprostinil Solution – This drug would be used to treat pulmonary hypertension and chronic obstructive pulmonary disease. Drug is currently in phase III.
  - Oral Treprostinil – This drug would be used to treat pulmonary hypertension and heart failure with a preserved ejection fraction. Drug is currently in phase III.
  - Dinutuximab – This drug would be used to treat small cell lung cancer. Drug is currently in phase II.
  - Irinotecan – This drug would be used to treat small cell lung cancer. Drug is currently in phase III.
  - Topotecan – This drug would be used to treat small cell lung cancer. Drug is currently in phase III.
- ♦ ***Stock's 52-week high and low:*** \$130.00 and \$100.06
- ♦ ***Partners:*** Northwell Health, 3D Systems, Lee's Pharmaceutical, Arena Pharmaceuticals, Samumed, Mochida Pharmaceutical, and Lung Biotechnology, Inc.



# **MediCapital Inc.**

12649 S. Jackson Rd., Edinburg, TX. 78535

## **Crucell NV**

Crucell NV *has* been in business since 2000. Crucell NV is a biotechnology company that specializes in vaccines and biopharmaceutical technologies. In 2010, Crucell NV was purchased by Janssen Pharmaceutical Companies of Johnson & Johnson.

- ♦ ***Drugs in Clinical Trials:***
  - Combination of cetrelimab with apalutamide – This drug would be used to treat patients with Castration-Resistant Prostatic Neoplasms. Drug is currently in Phase I
  - Erdafitinib – This drug would be used to treat patients with Urothelial Cancer and study patients using erdafitinib versus standard of care which usually consists of chemotherapy (docetaxel or vinflunine). Drug is currently in Phase III.
  - Niraparib in combination with Abiraterone Acetate and Prednisone – This drug would be used to treat patients with Metastatic Prostate Cancer. Drug is currently in Phase III.
  - Ibrutinib Plus Venetoclax (I+VEN) - This drug would be used to treat Leukemia, Lymphocytic, Chronic, B-Cell. Drug is currently in Phase III.
- ♦ ***Stock's 52-week high and low:*** \$34.90 and \$34.60
- ♦ ***Partners:*** The Crohn's & Colitis Foundation of America, Creaky Joints, The Arthritis Foundation, Spondylitis Association of America, and The National Psoriasis Foundation

## **Mannkind Corp.**

Mannkind Corporation has been in business since 1991. Mannkind Corporation specializes on the discovery, development, and commercialization of therapeutic products for patients that suffer with diseases such as diabetes and pulmonary arterial hypertension.

- ♦ ***Drugs in Clinical Trials:***
  - Afrezza Inhalation Powder – This will be used to treat type I and type II diabetes mellitus in adults. Drug has completed phase IV and has been approved.
  - Treprostinil Technosphere – This drug will be used to treat pulmonary arterial hypertension. Drug is in Phase III
  - Palonosetron Technosphere – This drug will be used to treat chemotherapy-induced nausea and vomiting. Drug is in Phase I.
- ♦ ***Stock's 52-week high and low:*** \$3.04 and \$0.94
- ♦ ***Partners:*** United Therapeutics, and Receptor Life Sciences



**MediCapital Inc.**  
12649 S. Jackson Rd., Edinburg, TX. 78535

**Recommendation:**

MediCapital, Inc. after diligent review has chosen to invest in both United Therapeutics and Crucell NV. These two companies have multiple clinical drug trials in the process to cure cancer related diseases. They have both been in business for over nineteen years and are extremely dedicated to their craft which is to help patients treat this nonbiased disease known as cancer. United Therapeutics and Crucell NV have the man power, leading technologic knowledge, excellent partnerships, and the passion that MediCapital is looking for.